ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J. Berger, M.D., founder, chairman and chief executive officer of ARIAD, was named by Ernst & Young as a 2013 Entrepreneur Of The Year for the New England region. The award recognizes entrepreneurial excellence in ten industry categories. Dr. Berger was among thirty-two finalists who represented the region’s top executives across all major industries, and he received his award in the biotechnology category. The award recognizes outstanding entrepreneurs at high-growth companies that demonstrate excellence and extraordinary success in innovation, financial performance, personal commitment to their businesses and communities, and other areas.
ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

ARIAD Chief Executive Officer, Harvey J. Berger, M.D (Photo: Business Wire)

“It is an honor to be recognized as an Entrepreneur Of The Year in New England by Ernst & Young, “stated Dr. Berger. “This award is a testament to the outstanding work of ARIAD employees in bringing life-transforming medicines to cancer patients. In the last twenty years, we have remained dedicated to advancing scientific and medical research and now making our new cancer medicine, Iclusig ®, available to patients around the world. Our employees have provided the essential support that has allowed us to position the company for strong growth and expansion.”

Ernst & Young recognizes Entrepreneur of the Year winners in 25 US regions. Regional winners go on to compete at the national level. Award winners in several national categories, as well as the National Entrepreneur Of The Year Overall Award winner, will be announced at the annual awards gala in Palm Springs, California, on November 16, 2013.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter ( @ARIADPharm).

About Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 167,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

For more information, please visit ey.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130628005285/en/

Copyright Business Wire 2010

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)